Status:

COMPLETED

Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety

Lead Sponsor:

Creighton University

Collaborating Sponsors:

AstraZeneca

Conditions:

Alcoholism

Anxiety Disorders

Eligibility:

All Genders

19-65 years

Phase:

PHASE4

Brief Summary

Alcohol use disorders (AUDs) are a major problem facing our society. Their treatment is complex, and involves multiple behavioral and pharmacotherapy interventions. There are 3 approved medications fo...

Detailed Description

STUDY OBJECTIVES: The objective of this proposal is to study the efficacy of the medication Seroquel SR for the treatment of alcohol dependence and co-morbid anxiety in a prospective double blind pla...

Eligibility Criteria

Inclusion

  • Diagnosis of alcohol dependence and an anxiety disorder (generalized anxiety disorder, post traumatic disorder, panic disorder, obsessive compulsive disorder, etc.) based on Mini-International Neuropsychiatric Interview (MINI) for DSM IV.
  • Subject reports a minimum of 48 standard alcoholic drinks (or an average of 12 drinks/wk) in a consecutive 30-day period (i.e., a minimum of 40% days drinking), and has 2 or more days of heavy drinking (defined as ≥5 drinks/day in males and ≥4 drinks/day in females) in this same period as measured by the Time Line Follow Back.
  • Male and female patients between 19-65 years of age.
  • Ability to provide informed consent.
  • Medically and psychiatrically stable defined as not requiring inpatient treatment.

Exclusion

  • Inability to provide informed consent.
  • Need for inpatient treatment
  • Need for inpatient detoxification for substance other than alcohol
  • Evidence of active dependence on a substance other than alcohol (with the exception of nicotine) as assessed by a urine drug screen.
  • Medically or psychiatrically unstable patients, defined as requiring inpatient treatment.
  • Pregnancy, nursing or refusal to use a reliable method of birth control in women.
  • Current treatment with other antipsychotic medications, which cannot be switched to Seroquel SR.
  • Patients with known allergy to Seroquel IR/SR or treatment failure to Seroquel IR/SR.
  • Exclude patients (pts) with unstable diabetes.
  • Exclude pts over 65
  • Exclude pts with dementia

Key Trial Info

Start Date :

February 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2008

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00352469

Start Date

February 1 2006

End Date

November 1 2008

Last Update

December 8 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Creighton University Department of Psychiatry

Omaha, Nebraska, United States, 68131